Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
Participants will randomly receive either the vaccine candidate or placebo in two doses, administered 21 days apart. Two-thirds of volunteers will receive intramuscular injections of the vaccine and one-third will receive placebo. A blinded crossover is planned to take place six months after the initial set of vaccinations to ensure that all trial participants receive active vaccine. Participants will be monitored for safety for up to two years following the final dose.
"Through the expansion of our PREVENT-19 clinical trial, we hope to build upon the encouraging safety and efficacy data generated to-date in adults for our vaccine candidate and to play a significant global role in offering vaccination to as many people as possible across age groups to end the suffering caused by the pandemic," said
Title: Safety, efficacy, and uptake of COVID-19 vaccines
Afternoon Session: COVID-19: Vaccine Response & Approaches
Title: Novavax COVID-19 Program Update
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using
NVX-CoV2373 is being evaluated in two pivotal Phase 3 trials: a trial in the
NVX-CoV2373 is stored and stable at 2°- 8°C, allowing the use of existing vaccine supply chain channels for its distribution. It is packaged in a ready-to-use liquid formulation in 10-dose vials.
Novavax Forward Looking Statements
Statements herein relating to the future of
View original content to download multimedia:http://www.prnewswire.com/news-releases/novavax-initiates-pediatric-expansion-for-phase-3-clinical-trial-of-covid-19-vaccine-301282123.html